Skip to main content

Table 3 Prevalence of pulmonary hypertension according to treatment group

From: Venous thromboembolism and persistent pulmonary hypertension in cancer patients: a cross-sectional study

Treatment group Pulmonary hypertension
1: No previous antineoplastic chemotherapy or chest radiotherapy (n = 345) 53 (15.4 %)
2: Previous chemotherapya without anthracyclines (n = 114) 18 (15.8 %)
3: Previous chemotherapy with anthracyclines (n = 79) 11 (13.9 %)
4: Previous chest radiotherapy from 1995 onwards (n = 74) 10 (13.5 %)
5: Pre-1995 chest radiotherapy (n = 23) 8 (34.8 %)
  1. aAlkylating agents, antimetabolites, microtubule-targeting agents, molecular-targeting agents. The treatment groups were not distinct from each other. Hence, no between-group comparisons could be made. The high proportion of patients with PH in group 5 probably relates to the high prevalence of atrial fibrillation and left heart disease among the 23 patients who had undergone pre-1995 radiotherapy (atrial fibrillation, 21.7 %; impaired left ventricular systolic function, 8.7 %; significant valvular heart disease, 34.8 %; left ventricular hypertrophy, 30.4 %)